secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001140361-25-040664
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q3 2025 KIMMTRAK sales $103.7M, up 29% YoY; net loss $0.2M vs profit $8.7M
--------------------------------------------------------------------------------

- KIMMTRAK net revenue $103.7M (Q3); $295.5M YTD, up 31% YoY; US sales $67.3M, Europe $33.5M.
- Net loss $(0.2)M vs profit $8.7M in Q3 2024; diluted EPS $(0.00) vs $0.17.
- IDMC recommended 160 mcg dose for brenetafusp in Phase 3 PRISM-MEL-301; on track to complete enrollment in 1H 2026.
- Cash, equivalents & marketable securities $892.4M as of Sept 30, 2025; expects $65M rebate payments in Q4.
- Phase 3 TEBE-AM (tebentafusp) enrollment on track for 1H 2026 completion; multiple pipeline programs advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/0001140361-25-040664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125040664/ef20058378_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-040664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer